Meijboom KE, Abdallah A, Fordham NP, Nagase H, Rodriguez T, Kraus C, Gendron TF, Krishnan G, Esanov R, Andrade NS, Rybin MJ, Ramic M, Stephens ZD, Edraki A, Blackwood MT, Kahriman A, Henninger N, Kocher JA, Benatar M, Brodsky MH, Petrucelli L, Gao FB, Sontheimer EJ, Brown RH, Zeier Z, Mueller C. CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro. Nat Commun. 2022 Oct 21;13(1):6286. [PubMed link]
Recent Posts
- Feature: UHealth’s Qalsody Clinic Provides Cutting-Edge Care for ALS Patients
- The New York Times Feature: In a Milestone for A.L.S., a Treatment Helps Some Patients Improve
- CReATe Author Series Ep. 18 – Dr. Michael Benatar on MMI as a prodromal stage of ALS
- Walk to Defeat ALS Miami 2026
- Save the Date! 2026 Annual ALS Patient Symposium
Recent Comments